Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., Geba, G. P. · 2012 · Clinical & Experimental Allergy

Abstract

Summary: Interleukin‐5 is a Th2 homodimeric cytokine involved in the differentiation, maturation, migration, development, survival, trafficking and effector function of blood and local tissue eosinophils, in addition to basophils and mast cells. The IL‐5 receptor (IL‐5R) consists of an IL‐5‐specific α subunit that interacts in conformationally dynamic ways with the receptor's βc subunit, an aggregate of domains it shares with binding sites of IL‐3 and granulocyte‐macrophage colony‐stimulating factor. IL‐5 and IL‐5R drive allergic and inflammatory immune responses characterizing numerous diseases, such as asthma, atopic dermatitis, chronic obstructive pulmonary disease, eosinophilic gastrointestinal diseases, hyper‐eosinophilic syndrome, C hurg‐S trauss syndrome and eosinophilic nasal polyposis. Although corticosteroid therapy is the primary treatment for these diseases, a substantial number of patients exhibit incomplete responses and suffer side‐effects. Two monoclonal antibodies have been designed to neutralize IL‐5 (mepolizumab and reslizumab). Both antibodies have demonstrated the ability to reduce blood and tissue eosinophil counts. One additional monoclonal antibody, benralizumab (MEDI‐563), has been developed to target IL‐5R and attenuate eosinophilia through antibody‐dependent cellular cytotoxicity. All three monoclonal antobodies are being clinically evaluated. Antisense oligonucleotide technology targeting the common βc IL‐5R subunit is also being used therapeutically to inhibit IL‐5‐mediated effects (TPI ASM8). Small interfering RNA technology has also been used therapeutically to inhibit the expression of IL‐5 in animal models. This review summarizes the structural interactions between IL‐5 and IL‐5R and the functional consequences of such interactions, and describes the pre‐clinical and clinical evidence supporting IL‐5R as a therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2011.03854.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 215

Metadata

Authors
Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., & Geba, G. P.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2011-09-23
Volume
42
Issue
5
Pages
712-737
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2056743382
Cited by
215
References
3
FWCI
11.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor. https://app.cochat.ai/papers/10.1111/j.1365-2222.2011.03854.x
The paper
Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M., & Geba, G. P. (2012). Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2011.03854.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.